S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane.

Slides:

Advertisements

Similar presentations

Treatment of Relapsed Osteosarcoma After Contemporary Therapy: The Memorial Sloan-Kettering Experience Chou AJ, Merola PR, Vyas Y, Wexler L, Gorlick R,

Advertisements

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent.

Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.

IMPACT OF TUMOR MORCELLATION ON THE NATURAL HISTORY OF UTERINE LEIOMYOSARCOMA César Serrano, Titilope Oduyebo, Judith Manola, Yang Feng, Michael G. Muto,

Clinicopathologic Characteristics and Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery Emily.

Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

A Propensity-matched Study of Lobectomy Versus Segmentectomy for Radiologically Pure Solid Small-sized Non-small Cell Lung Cancer Terumoto Koike 1, Seijiro.

AATS Postgraduate Course April 26, 2015 N2 - Current Evidence: Is There Role for Surgery? Is There a Role for Postop Radiation for Surprise N2? Linda W.

Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma

SURGEONS ROLE AND INVOLVEMENT IN SBRT PROGRAM Stephen R. Hazelrigg, M.D. Professor and Chair, Cardiothoracic Surgery Southern Illinois University, School.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

Kerrington Smith, M.D. CTOS Nov 14, 2008

Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.

Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.

MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.

Cardiac events after treatment with high dose radiation therapy +/- chemotherapy for non-small cell lung cancer Linglong Tang, Anwen Liu, Daniel Gomez,

Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.

Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.

Involved Field Radiotherapy versus No Further Treatment in Patients with Clinical Stages IA/IIA Hodgkin Lymphoma and a “Negative” PET Scan After 3 Cycles.

S L I D E 0 Elderly Patients Undergoing SBRT for Inoperable Early Stage NSCLC Achieve Similar Outcomes to Younger Patients Brandon R. Mancini, Henry S.

Multicenter Study of Down-staging of Hepatocellular Carcinoma (HCC) to within Milan Criteria before Liver Transplantation Neil Mehta, MD; Jennifer Guy,

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma.

NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.

Surgery for lung cancer – a review

CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.

on behalf of the ACOSOG Z4032 Investigators

Title: Stereotactic Ablative Radiotherapy (SABR) can be Safe and Effective for Treatment of Central and Ultra-Central Lung Tumors. Author: Aadel Chaudhuri,

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.

Conflict of Interest Declaration: Nothing to Disclose Presenter: Sophie Lamoureux Title of Presentation: A Comparison of Stereotactic Body Radiotherapy.

Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.

Outcomes of Stereotactic Ablative Radiotherapy (SABR) for a Second Primary Lung Cancer (SPLC): Evidence in Support of Routine CT Surveillance C. J.A. Haasbeek,

ACRIN 6682 Phase II Trial OF 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/4/08.

The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and.

Tumor Location Correlates with Radiation Pneumonitis after Stereotactic Body Radiation Therapy (SBRT) for Primary and Oligometastatic Lesions of the Lung.

Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

Erlotinib Therapy in Non Small Cell Lung Cancer Patients - Survival of Patients on Reduced Erlotinib Doses M. Pesek 1, J. Krejci 1, J. Skrickova 2, P.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.

The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.

DEPT OF RADIATION ONCOLOGY Prognostic Value of Post-Radiotherapy FDG PET in Head and Neck Cancer after Intensity Modulated Radiation Treatment Heming Lu.

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

Brain imaging prior to lung cancer resection

Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.

Compassionate People World Class Care

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Prognosis of younger patients in non-small cell lung cancer

Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.

Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Pulmonary nodules discovered on CT scan of the chest

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Presentation transcript:

S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane Lloyd MD, Eileen Harder BS, Brandon R. Mancini MD, Charles E. Rutter MD, Roy H. Decker MD PhD

S L I D E 1 Purpose/Objectives Staging workup SBRT of patients with early stage NSCLC selectively includes PET imaging followed by invasive mediastinal staging with endobronchial ultrasound (EBUS) or mediastinoscopy to confirm nodal status. Whether the addition of these invasive procedures to the staging workup improves outcomes has not been established. In this large single-institution retrospective analysis, we investigated whether invasive staging with nodal sampling improved outcomes in patients treated with SBRT when compared to PET staging alone.

S L I D E 2 Cohort 270 patients analyzed Median follow-up of 20.2 months. 189 underwent PET/CT imaging only 81 had invasive mediastinal staging despite having negative nodes by PET/CT PET Only (%) Mediastinal Staging (%) p-value Overall Gender Male93 (49.2)35 (43.2) 0.22 Female96 (50.8)46 (56.8) Age < 70 years53 (28.0)28 (34.6) 0.18 ≥ 70 years136 (72)53 (65.4) ECOG Performance Score (77.2)64 (79.0) (22.8)17 (21.0) Smoking History No5 (2.6)2 (2.5) 0.65 Yes184 (97.4)78 (97.5) Type of mediastinal Staging EBUS47 (58.0) Mediastinoscopy32 (40.0) T Stage T1154 (79.0)61 (67.0) 0.03 T241 (21.0)30 (33) Central Tumor Location No86 (60.1)25 (33.3) < Yes57 (39.9)50 (66.7) Synchronous Primaries No180 (95.7)69 (85.2) Yes8 (4.3)12 (14.8) Prior Dx of Cancer No82 (43.4)41 (50.6) 0.17 Yes107 (56.6)40 (49.4) BED of SBRT Treatment < (7.9)7 (8.6) 0.51 ≥ (92.1)74 (91.4)

S L I D E 3 Overall Survival Median OS: 29.2 mos (PET Only) vs 22.4 mos (Invasive) p=0.16

S L I D E 4 Local Recurrence Free Survival 2-year LRFS 82.5% vs. 91.5% p = 0.60

S L I D E 5 Regional Recurrence Free Survival 2-year RRFS 86.7% vs. 87.7% p = 0.95

S L I D E 6 Distant Recurrence Free Survival 2-year DRFS 79.2% vs. 92.2% p = 0.095

S L I D E 7 Multivariate Analysis: Overall Survival Factors included in model: –Tumor location (central vs. peripheral) –T stage –Staging method (PET Only vs. Invasive) –Synchronous primaries –Prior Lung Cancer –Other Primary Cancer –Performance Status –BED (categorical, 100) –Age ( 70) HR (95% CI)P value T Stage T11.0 T21.72 (1.09 – 2.71)P = 0.02 All other factors NS (p > 0.05) Factor significant on MVA:

S L I D E 8 Conclusions Mediastinal staging in the pre-treatment workup does not appear to improve OS, or RFS when compared to PET imaging alone, even when factors such as T stage, tumor location, BED and synchronous tumors are included in the model. Our analysis did not find a significant benefit to mediastinal staging in patients with early-stage NSCLC undergoing SBRT.